Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The different drug formulations of menopausal hormone therapy (HT) may determine the risk of venous thromboembolism (VTE), according to a new study. It is known that combined estrogen-progesterone therapy has a higher risk of VTE than estrogen-only therapy, and oral therapy has a higher risk than transdermal therapy.

Pharmacology Watch: Menopausal Hormone Therapy and the Risk for VTE, AD